{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine transaminase', 'AST', 'Aspartate aminotransferase', 'ATS', 'American Thoracic Society', 'CAT', 'COPD Assessment Test', 'CI', 'Confidence Intervals', 'CID', 'Clinically important deterioration', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CPK', 'Creatine phosphokinase', 'CRF', 'Case Report Form', 'CV', 'Cardiovascular', 'DPI', 'Dry Powder Inhaler', 'DRE', 'Disease Related Event', 'DNA', 'Deoxyribonucleic acid', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'eDiary', 'Electronic Diary', 'eMDI', 'Electronic Metered Dose Inhaler', 'E-RS', 'Evaluating Respiratory Symptoms- COPD Tool', 'ERS', 'European Respiratory Society', 'FEV1', 'Forced Expiratory Volume in One Second', 'FVC', 'Forced Vital Capacity', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GSK', 'GlaxoSmithKline', 'IB', 'Investigator Brochure', 'ICF', 'Informed Consent Form', 'ICS', 'Inhaled Corticosteroid', 'IEC', 'Independent Ethics Committee', 'IP', 'Investigational product', 'INR', 'International normalized ratio', 'IRT', 'Interactive Response Technology', 'ITT', 'Intent-to-Treat', 'IUD', 'Intrauterine Device', 'IUS', 'Intrauterine System', 'LABA', 'Long Acting Beta-Agonist', 'LAMA', 'Long-acting Muscarinic Receptor Antagonists', 'LDH', 'Lactate dehydrogenase', 'LTOT', 'Long Term Oxygen Therapy', '68']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'mcg', 'Microgram', 'MCID', 'Minimal Clinically Important Difference', 'MDI', 'Metered Dose Inhaler', 'mL', 'Milliliter', 'mMRC', 'Modified Medical Research Council', 'MMRM', 'Mixed Models Repeated Measures', 'MSDS', 'Material Safety Data Sheet', 'NYHA', 'New York Heart Association', 'OTC', 'Over the Counter', 'PGx', 'Pharmacogenetic', 'PIL', 'Patient Information Leaflet', 'PK', 'Pharmacokinetic', 'PP', 'Per Protocol', 'prn', 'As required', 'QTc', 'QT interval corrected for heart rate', 'RAP', 'Reporting and Analysis Plan', 'SABA Short Acting Beta-Agonist', 'SAE', 'Serious Adverse Event', 'SD', 'Standard Deviation', 'SmPC', 'Summary of Product Characteristics', 'SRT', 'Safety Review Team', 'TDI', 'Transition Dyspnea Index', 'RAMOS NG', 'Randomization and medication ordering system new', 'generation', 'ULN', 'Upper Limit of Normal', 'UMEC', 'Umeclidinium (GSK573719)', 'UMEC/VI', 'Umeclidinium & Vilanterol as a fixed dose combination', 'VI', 'Vilanterol Trifenate', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'ANORO', 'E-RS', 'DISKUS', 'EXCACT', 'ELLIPTA', 'INCRUSE', 'SEREVENT', '69']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.2.', 'Appendix 2: Liver Safety Required Actions and Follow up', 'Assessments', 'Phase III-IV liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'ALT-absolute', 'ALT 8xULN', 'ALT Increase', 'ALT 5xULN but <8xULN persists for >2 weeks', 'ALT 3xULN but <5xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT > 3xULN and bilirubin > 2xULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT 5xULN but <8xULN and cannot be monitored weekly for >2 weeks', 'Monitor', 'ALT 3xULN but <5xULN and cannot be monitored weekly for >4 weeks', 'Symptomatic\u00b3', 'ALT > 3xULN associated with symptoms (new or worsening) believed to be', 'related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Only in those with underlying chronic', 'Complete the liver event CRF and complete', 'hepatitis B at study entry (identified by', 'an SAE data collection tool if the event also', 'positive hepatitis B surface antigen)', 'meets the criteria for an SAE\u00b2', 'quantitative hepatitis B DNA and hepatitis', 'delta antibody5.', 'Perform liver event follow up assessments', 'Blood sample for pharmacokinetic (PK)', 'Monitor the subject until liver chemistries', 'analysis, obtained within a week after last', 'resolve stabilize, or return to within normal', 'dose6', 'ranges. baseline (see MONITORING below)', 'Serum creatine phosphokinase (CPK) and', 'Do not restart/rechallenge subject', 'lactate dehydrogenase (LDH).', 'with study treatment. Permanently', 'Fractionate bilirubin, if total', 'discontinue study treatment and may', 'bilirubin>2xULN', 'continue subject in the study for any', 'protocol specified follow up assessments', 'Obtain complete blood count with', 'differential to assess eosinophilia', 'Record the appearance or worsening of', 'clinical symptoms of liver injury, or', '70']\n\n###\n\n", "completion": "END"}